Osimertinib

Osimertinib is a selective, irreversible, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It is specifically designed to target EGFR mutations that are known to drive the growth and proliferation of certain types of cancer. These mutations are commonly found in lung cancer, where they occur in approximately 10-15% of all cases.
Osimertinib is primarily used for the treatment of patients with non-small cell lung cancer (NSCLC) whose tumors carry specific EGFR mutations. In particular, it is indicated for those individuals who have already undergone treatment with other EGFR-TKIs and are experiencing disease progression or relapse. The medication works by inhibiting the activity of EGFR and its downstream signaling pathways, thereby preventing cancer cells from proliferating and spreading to other parts of the body.
Some potential side effects of osimertinib may include skin rash, diarrhea, nail disorder, and increased levels of liver enzymes. Patients should report any adverse reactions to their healthcare provider for proper evaluation and management. As with any medication, it is essential for individuals taking osimertinib to discuss their medical history, current health conditions, and any other medications or supplements they may be taking to ensure safe and effective treatment.